“Insomnia in Elderly Patients: Recommendations for Pharmacological Management”. Drugs Aging35 (9): 791–817. (September 2018). doi:10.1007/s40266-018-0569-8. PMID 30058034.
“Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study”. J Clin Sleep Med13 (11): 1289–1299. (November 2017). doi:10.5664/jcsm.6800. PMC 5656478. PMID 29065953. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656478/.
“Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant”. J Clin Pharmacol57 (1): 96–104. (January 2017). doi:10.1002/jcph.785. PMID 27338807.
関連項目
スボレキサント
ダリドレキサント
外部リンク
“Lemborexant” (英語). Drug Information Portal. U.S. National Library of Medicine. 2021年8月27日閲覧。